Cue Biopharma, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 28/100
What the filing says
Cue Biopharma entered into an exclusive licensing agreement with Ascendant Health Sciences Limited dated April 30, 2026, to develop and commercialize a humanized IgG1 monoclonal antibody (UB-221) designed to neutralize IgE and inhibit its production. Cue paid a $15 million upfront fee and is obligated to pay additional milestone payments (including Phase 2, manufacturing technology transfer, data transfer, development, and net sales milestones totaling substantial amounts), plus tiered royalties on net sales. The deal grants Cue exclusive rights in the Cue Territory (worldwide excluding Ascendant Territory: mainland China, Hong Kong, Macau, Taiwan) with Ascendant retaining exclusive rights in its territory.
Why this rating
Modest deal for ~$52M company. $15M upfront plus contingent payments are material but non-transformational. Company obtains exclusive development rights to promising anti-IgE molecule, but early-stage asset with significant development risk ahead.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.